Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACHIEVE: Chemo-Immunotherapy vs Immunotherapy Alone in Older Adults with Advanced NSCLC
NCT06096844Phase 3Recruiting
- Sponsor
- National Cancer Institute
- Start
- Jul 2024
- Primary completion
- Apr 2039
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of pembrolizumab, carboplatin, paclitaxel, Paclitaxel Micelles for Injection, pemetrexed in non-small cell lung cancer (NSCLC), sponsored by National Cancer Institute. Started Jul 2024; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06096844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06096844.